Role of Modified Frailty Index in Predicting Oncologic Outcomes From Moderately Hypofractionated Radiotherapy for Patients with Stage I-IIB Non-Small Cell Lung Cancer
JournalInternational Journal of Radiation Oncology - Biology - Physics
MetadataShow full item record
AbstractModerately hypofractionated regimens have emerged as an alternative to stereotactic body radiotherapy for patients with central/ultracentral non-small cell lung cancer (NSCLC) who are medically inoperable due to age, poor performance status (PS) or associated comorbidity and who may be at a higher risk of severe toxicity. In the present study, we utilize a modified frailty index (mFI) to identify frail patients and hypothesize that frailty could better stratify clinical outcomes in these patients.
Rights/TermsCopyright © 2021 Published by Elsevier Inc.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18480